Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen
results in tumor eradication Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tumor eradication SEATTLE, April 09, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced data from its T cell programs are being presented at the virtual American Association for C